Literature DB >> 26730880

How you ask is what you get: Framing effects in willingness-to-pay for a QALY.

Marlies Ahlert1, Friedrich Breyer2, Lars Schwettmann3.   

Abstract

In decisions on financing new and innovative health care technologies a central question is how to determine the value citizens place on the gains in health and life expectancy that result from respective medical treatments. We report results of surveys of four representative samples of the German population. In 2010 and 2012, in total about 5000 respondents were asked for their willingness-to-pay (WTP) for either an extension of their life or an improvement in their health corresponding to a gain of one quality-adjusted life year (QALY). Specific changes of the study design allow for ceteris paribus comparisons of different survey versions. While the initial version exactly copied a questionnaire used in the EuroVaQ (European Value of a QALY) project, which was conducted in nine European countries and Palestine, but not in Germany, in other versions the wording and the survey technique were modified. The findings show that the technique of posing the questions plays an important role when respondents are asked to imagine being in hypothetical situations. This clearly refers to the wording of the questions and the survey setting (personal or online interview). But even simple design elements such as putting a yes/no filter in front greatly affect the answers in terms of both the frequency of zero WTP and the distribution of positive amounts. From the different results, we conclude that it is inevitable to conduct studies comprising a broad variety of versions when trying to elicit WTP for a specific type of QALY in order to achieve an array of values combined by insights into the principles of their sensitivity.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EuroVaQ; Germany; QALY; Survey design; Willingness-to-pay

Mesh:

Year:  2015        PMID: 26730880     DOI: 10.1016/j.socscimed.2015.11.055

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  11 in total

1.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

2.  Cost-effectiveness of SQ® HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany.

Authors:  William Green; Jörg Kleine-Tebbe; Ludger Klimek; Julie Hahn-Pedersen; Jakob Nørgaard Andreasen; Matthew Taylor
Journal:  Clinicoecon Outcomes Res       Date:  2017-02-16

3.  Health shock and preference instability: assessing health-state dependency of willingness-to-pay for corrective eyeglasses.

Authors:  Muhammed Nazmul Islam; Atonu Rabbani; Malabika Sarker
Journal:  Health Econ Rev       Date:  2019-11-07

4.  Cost utility analysis of the SQ(®) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting.

Authors:  J Hahn-Pedersen; M Worm; W Green; J Nørgaard Andreasen; M Taylor
Journal:  Clin Transl Allergy       Date:  2016-09-07       Impact factor: 5.871

5.  Cost-Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model Simulation.

Authors:  Mathias Baumann; Tom Stargardt; Simon Frey
Journal:  Appl Health Econ Health Policy       Date:  2020-08       Impact factor: 2.561

6.  Willingness to pay for an early warning system for infectious diseases.

Authors:  Sebastian Himmler; Job van Exel; Meg Perry-Duxbury; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2020-03-16

Review 7.  Understanding the global measurement of willingness to pay in health.

Authors:  Jean A McDougall; Wesley E Furnback; Bruce C M Wang; Jörg Mahlich
Journal:  J Mark Access Health Policy       Date:  2020-02-15

8.  Differential discounting in the economic evaluation of healthcare programs.

Authors:  Jürgen John; Florian Koerber; Mareike Schad
Journal:  Cost Eff Resour Alloc       Date:  2019-12-17

9.  Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.

Authors:  Benjamin Birkner; Jürgen Rech; Tom Stargardt
Journal:  PLoS One       Date:  2020-01-02       Impact factor: 3.240

10.  Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator.

Authors:  Moritz Hadwiger; Fabian-Simon Frielitz; Nora Eisemann; Christian Elsner; Nikolaos Dagres; Gerhard Hindricks; Alexander Katalinic
Journal:  Appl Health Econ Health Policy       Date:  2021-01       Impact factor: 2.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.